Article Versions Notes

Herr F, Dekeyser M, Le Pavec J, Desterke C, Chiron A-S, Bargiel K, Mercier O, Vernochet A, Fadel E, Durrbach A. mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4⁺CD57⁺ T Cells In Vivo and In Vitro. Pharmaceutics. 2023; 15(4):1299. https://doi.org/10.3390/pharmaceutics15041299

Herr, Florence, Manon Dekeyser, Jerome Le Pavec, Christophe Desterke, Andrada-Silvana Chiron, Karen Bargiel, Olaf Mercier, Amelia Vernochet, Elie Fadel, and Antoine Durrbach. 2023. "mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4⁺CD57⁺ T Cells In Vivo and In Vitro" Pharmaceutics 15, no. 4: 1299. https://doi.org/10.3390/pharmaceutics15041299

Herr, F., Dekeyser, M., Le Pavec, J., Desterke, C., Chiron, A.-S., Bargiel, K., Mercier, O., Vernochet, A., Fadel, E., & Durrbach, A. (2023). mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4⁺CD57⁺ T Cells In Vivo and In Vitro. Pharmaceutics, 15(4), 1299. https://doi.org/10.3390/pharmaceutics15041299